

OLARTEMoure

OLARTE MOURE & ASOCIADOS LTDA.

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 10-160879- -00003-0000

Fecha: 2011-04-04 18:02:36 Dep. 2020 DIR.NUEVASCR
Tra. 11 PATENTEIYI Eve: 378 FASENACIONALI
Act. 444 RESPUESTAREQUE Folios: 15

Señores

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

DIRECCIÓN DE NUEVAS CREACIONES

E. _____ S. _____ D. _____

Ref: Expediente N°. 10-160.879

Solicitud de Patente de Invención titulada: "DERIVADOS DE
PIPERIDINILINDOL COMO INHIBIDORES DE ALDOSTERONA SINTASA"

Solicitante: NOVARTIS AG

Nuestra Ref: P2010/000189

RESPUESTA AL OFICIO N° 2235 NOTIFICADO

POR FIJACION EN LISTA No. 41 DE FECHA 11 DE FEBRERO DE 2011,

(EXAMEN DE FORMA)

CARLOS R. OLARTE, mayor de edad y vecino de Bogotá, identificado tal como aparece al pie de mi firma, en mi carácter de apoderado de la sociedad en referencia, me permito dar respuesta al auto proferido por ese Despacho, dentro del término legal previsto en el artículo 39 de la Decisión 486 en los siguientes términos:


1. En respuesta a la primera observación del Examinador me permito presentar un nuevo título: **"DERIVADOS DE PIPERIDINILINDOL COMO INHIBIDORES DE ALDOSTERONA SINTASA"**, el cual permite identificar claramente el objeto de la solicitud de patente según lo previsto en la Regla 4.3 PCT, Artículos 26 y 27 de la Decisión 486 y Circular Única de la SIC numeral 5.2.9.

355

2

2. En respuesta a la segunda observación del Examinador, me permito aportar junto al presente memorial un (1) documento de cesión debidamente legalizado, según los artículos 259 y 260 del CPC, en los que consta la cesión de cuatro (4) inventores al solicitante, junto con su correspondiente traducción, según lo previsto en el Art. 26-k de la Decisión 486.

Atentamente,



CARLOS R. OLARTE
C.C. 79.782.747 de Bogotá
T.P. 74.295

Adjunto: Documento de Cesión

356

239

Caso de Patente: 52533

CESIÓN

Por buena y onerosa consideración, del cual se acusa recibo suficiente, nosotros

Chirstopher ADAMS	Ciudadano de los Estados Unidos de América	Novartis Institutes for BioMedical Research, Inc. 400 Technology Square Cambridge, MA 021139, US
Qi-Ying HU	Ciudadano de China	Novartis Institutes for BioMedical Research, Inc. 400 Technology Square Cambridge, MA 021139, US
Leslie Wighton MCQUIRE	Ciudadano de los Estados Unidos de América	Novartis Institutes for BioMedical Research, Inc. 400 Technology Square Cambridge, MA 021139, US
Julien PAPILLON	Ciudadano de Francia	Novartis Institutes for BioMedical Research, Inc. 400 Technology Square Cambridge, MA 021139, US

Por medio de la presente vendemos y transferimos a NOVARTIS AG, una compañía constituida bajo las leyes de la confederación Suiza, de Lichstrasse 35, 4056 Basilea, Suiza y sus sucesores, cesionarios y representantes legales todos nuestros derechos titulo e interés para todos los países del mundo, llamados de ahora en adelante colectivamente los CESIONARIOS) en y para (1) todos nuestros inventos y descubrimientos descritos en la solicitud de patente titulada:

COMPUESTOS ORGANICOS

Y presentada en la Oficina de Marcas y Patentes de los Estados Unidos el _____, 20__ y de acuerdo con la solicitud No. _____ *y/o presentada* en el RO/ _____ el _____, y de acuerdo con la Solicitud de Patente Internacional PCT/ _____, (2) dicha solicitud de patente identificada en (1), (3) todas las fases nacionales de dicha solicitud de patente internacional identificada en (1), (4) todas las demás solicitudes de patentes en todas las regiones y países que reivindiquen prioridad de la solicitud de patente provisional presentada en la oficina de Marcas y Patentes de los Estados Unidos el **27 de junio de 2008** y de acuerdo con las solicitud número **61/076,452**, (5) por todas las solicitudes de Patentes, todos los derechos de prioridad basados en la solicitud de Patente en Los Estados Unidos identificada en (4) en todos los países y regiones bajo la convención de Paris para la protección de la propiedad industrial, la Convención Inter-Americana relacionado con Patentes, Invenciones Diseños y Modelos Industriales y todos los demás convenios internacionales a los

MAURICE URF...
TRADUCCION E INTERPRETACION AL
INGLES
FOLIO MINUTERIA 1789 - 1983

[illegible]

2010-08-01

[illegible]

A

cuales esté suscrito o que intente hacerlo, y si la Patente de los Estados Unidos identificada en (4) es una solicitud de Patente provisional, bajo 35USC 119(e) (incluyendo el derecho a presentar solicitud de Patente en dichas invenciones y descubrimientos en nombre de los CESIONARIOS o sus designados o en nuestros nombres, a su elección y de acuerdo a las leyes aplicables en todos los países o regiones), (6) Todas las continuaciones o divisiones de cualquiera de las solicitudes de Patente en Los Estados Unidos o de solicitud de Patente Internacional identificada en (1) y cualquier solicitud de Patente dentro del rango de (4) (incluyendo futuras continuaciones y divisiones tales como, pero no limitadas a, continuaciones de continuaciones de divisiones), ((2)-(4) y (6) de aquí en adelante referenciadas como colectivas "las solicitudes de patentes"), (7) todas las Patentes que sean otorgadas en cualquiera de dichas solicitudes de Patente, (8) todas los registros de y confirmaciones de, y certificados de importación basados en, una o mas dichas Patentes y (9) todos los re-otorgamientos, renovaciones, y extensiones de dichas patentes, registros, confirmaciones y certificados de importación y certificados de re reexaminación, expedidos para dichas patentes y certificados de protección basados en dichas patentes y solicitudes para tales re otorgamientos, renovaciones, extensiones, certificados de re-exanimación y certificados de protección, así mismo para ser conservada y disfrutada por dichos CESIONARIOS y sus sucesores, asignados y representantes legales, en su totalidad por dichas patentes, registros, confirmaciones, certificados de importación, certificados de reexaminación, certificados suplementarios de protección, re otorgamientos, renovaciones y extensiones que puedan ser expedidas, proporcionar todos los términos para que todas las patentes puedan ser concedidas, para conservar y disfrutar plenamente y totalmente por nosotros, así mismo como lo haríamos si esta cesión no hubiera sido vendida y transferida.

*Nosotros por medio del presente autorizamos al CESIONARIO y sus representantes para incorporar en este instrumento el número de la solicitud y la fecha de presentación de dicha solicitud cuando esta sea notificada.

Y por medio de la presente nosotros convenimos y acordamos que en cualquier momento, (i) al requerirse y a expensas del CESIONARIO o sus sucesores asignados o representantes legales, ejecutaremos y entregaremos cualquier y todos los documentos necesarios y deseables para perfeccionar el titulo de los anteriores inventos o descubrimientos, solicitudes de patente, registros confirmaciones, certificados de importación, re-otorgamientos, renovaciones, extensiones, certificados de reexaminación, certificados de protección adicional dentro del rango de (8) y (9) a nombre del CESIONARIO, sus cesionarios, sucesores, u otros representantes legales, incluyendo la ejecución y consecución de cualquier y todo documento adicional que evidencie esta cesión y venta según sea necesario o deseable en la Oficina de Patentes u otra Oficina o Agencia para la Propiedad Intelectual o similar de cualquier país o región, (ii) al requerirse, pero a expensas del CESIONARIO o de sus sucesores, asignados, o representantes legales ejecutaremos todas las solicitudes dentro del rango de adicionales de Patente (3), (4) y (6) y todas las solicitudes dentro del rango (8) o (9) y (iii) y realizaremos las declaraciones necesarias juramentadas y realizaremos todos los

MAPA OFICE JURRE
TRADUCCION
INGLES ESPANOL
F.S. MINJUSTIA 17/3 1988

5

actos jurídicos necesarios para ello, sin compensación adicional, pero a expensas del CESIONARIO, sus sucesores, cesionarios, u otros representantes legales.

Ejecutado el 3 de abril de 2009
Firmado por Christopher ADAMS L.S.

RECONOCIMIENTO

(Estado de Massachusetts)
(Condado de Middlesex) s.s.:

El 3 de abril de 2009, personalmente compareció ante mi Christopher Adams, conocido del suscrito, y conocido del suscrito como la persona descrita en el anterior instrumento y quien lo suscribió, la cual reconoció que suscribió el mismo por su propia voluntad y para los fines expuestos en el mismo.

(sello)

(firmado: Allison Blake)
Mancomunidad de Massachusetts
Mi comisión vence el 17 de octubre de 2014

Ejecutado el 1 de abril de 2009
Firmado por Qi-Ying HU L.S.

RECONOCIMIENTO

(Estado de Massachusetts)
(Condado de Middlesex) s.s.:

El 1 de abril de 2009, personalmente compareció ante mi Qi-Ying HU, conocido del suscrito, y conocido del suscrito como la persona descrita en el anterior instrumento y quien lo suscribió, la cual reconoció que suscribió el mismo por su propia voluntad y para los fines expuestos en el mismo.

(sello)

(firmado: Allison Blake)
Mancomunidad de Massachusetts
Mi comisión vence el 17 de octubre de 2014

Ejecutado el 1 de abril de 2009
Firmado por Leslie Wighton MCQUIRE L.S.

RECONOCIMIENTO

(Estado de Massachusetts)
(Condado de Middlesex) s.s.:

MANIT/CE U.S. NOTARY
TRANSLATED & INTERPRETED
INGLES - ESPANOL - CHINESE
RES. MINJUR. 21-1-10-1-10

1. The first part of the report is a summary of the work done during the year.

2. The second part is a detailed account of the work done during the year.

3. The third part is a summary of the work done during the year.

4. The fourth part is a detailed account of the work done during the year.

5. The fifth part is a summary of the work done during the year.

6. The sixth part is a detailed account of the work done during the year.

7. The seventh part is a summary of the work done during the year.

8. The eighth part is a detailed account of the work done during the year.

9. The ninth part is a summary of the work done during the year.

10. The tenth part is a detailed account of the work done during the year.

11. The eleventh part is a summary of the work done during the year.

12. The twelfth part is a detailed account of the work done during the year.

13. The thirteenth part is a summary of the work done during the year.

14. The fourteenth part is a detailed account of the work done during the year.

15. The fifteenth part is a summary of the work done during the year.

16. The sixteenth part is a detailed account of the work done during the year.

17. The seventeenth part is a summary of the work done during the year.

18. The eighteenth part is a detailed account of the work done during the year.

19. The nineteenth part is a summary of the work done during the year.

20. The twentieth part is a detailed account of the work done during the year.

21. The twenty-first part is a summary of the work done during the year.

6

El 1 de abril de 2009, personalmente compareció ante mi Leslie Wighton MCQUIRE, conocido del suscrito, y conocido del suscrito como la persona descrita en el anterior instrumento y quien lo suscribió, la cual reconoció que suscribió el mismo por su propia voluntad y para los fines expuestos en el mismo.

(sello)

(firmado: Allison Blake)

Mancomunidad de Massachusetts

Mi comisión vence el 17 de octubre de 2014

Ejecutado el 1 de abril de 2009

Firmado por Julien PAPILLON L.S.

RECONOCIMIENTO

(Estado de Massachusetts)

(Condado de Middlesex) s.s.:

El 1 de abril de 2009, personalmente compareció ante mi Julien PAPILLON, conocido del suscrito, y conocido del suscrito como la persona descrita en el anterior instrumento y quien lo suscribió, la cual reconoció que suscribió el mismo por su propia voluntad y para los fines expuestos en el mismo.

(sello)

(firmado: Allison Blake)

Mancomunidad de Massachusetts

Mi comisión vence el 17 de octubre de 2014

ACEPTACIÓN DE LA CESIÓN

En referencia con la cesión realizada a NOVARTIS AG de una invención titulada "COMPUESTOS ORGANICOS" firmada por Christopher ADAMS, Qi-Ying HU, Leslie Wighton MCQUIRE y Julien PAPILLON; certificamos que dicha cesión ha sido aceptada por NOVARTIS AG.

NOVARTIS AG

Por: (Firma ilegible)
Nombre: Ella Rutschmann
Cargo: Firma autorizada
Fecha: 14 de abril de 2009

(Firma ilegible)
Sabine Zeller
Firma autorizada

MAJURO
TH/D/CTOR E INT
IN... SP... NO...
OFFICIAL
S... F...
[Handwritten signature]

1. The first step is to identify the problem. In this case, the problem is that the company is not meeting its sales targets.

1. The first step is to identify the problem or goal. This involves understanding the current situation and what needs to be achieved.

2025-01-01 2025-01-01
2025-01-01 2025-01-01

100-443887-1

1950-1951
1952-1953

1. The following information is provided for the year ended 31 December 2017:

	Revenue	Cost of Sales	Operating Expenses
Revenue	1000		
Cost of Sales		(400)	
Operating Expenses			(200)
Profit	400		

2. The following information is provided for the year ended 31 December 2018:

	Revenue	Cost of Sales	Operating Expenses
Revenue	1100		
Cost of Sales		(450)	
Operating Expenses			(220)
Profit	430		

3. The following information is provided for the year ended 31 December 2019:

	Revenue	Cost of Sales	Operating Expenses
Revenue	1200		
Cost of Sales		(500)	
Operating Expenses			(240)
Profit	460		

4. The following information is provided for the year ended 31 December 2020:

	Revenue	Cost of Sales	Operating Expenses
Revenue	1300		
Cost of Sales		(550)	
Operating Expenses			(260)
Profit	490		

5. The following information is provided for the year ended 31 December 2021:

	Revenue	Cost of Sales	Operating Expenses
Revenue	1400		
Cost of Sales		(600)	
Operating Expenses			(280)
Profit	520		

6. The following information is provided for the year ended 31 December 2022:

	Revenue	Cost of Sales	Operating Expenses
Revenue	1500		
Cost of Sales		(650)	
Operating Expenses			(300)
Profit	550		

7. The following information is provided for the year ended 31 December 2023:

	Revenue	Cost of Sales	Operating Expenses
Revenue	1600		
Cost of Sales		(700)	
Operating Expenses			(320)
Profit	580		

8. The following information is provided for the year ended 31 December 2024:

	Revenue	Cost of Sales	Operating Expenses
Revenue	1700		
Cost of Sales		(750)	
Operating Expenses			(340)
Profit	610		

9. The following information is provided for the year ended 31 December 2025:

	Revenue	Cost of Sales	Operating Expenses
Revenue	1800		
Cost of Sales		(800)	
Operating Expenses			(360)
Profit	640		

10. The following information is provided for the year ended 31 December 2026:

	Revenue	Cost of Sales	Operating Expenses
Revenue	1900		
Cost of Sales		(850)	
Operating Expenses			(380)
Profit	670		

11. The following information is provided for the year ended 31 December 2027:

	Revenue	Cost of Sales	Operating Expenses
Revenue	2000		
Cost of Sales		(900)	
Operating Expenses			(400)
Profit	700		

12. The following information is provided for the year ended 31 December 2028:

	Revenue	Cost of Sales	Operating Expenses
Revenue	2100		
Cost of Sales		(950)	
Operating Expenses			(420)
Profit	730		

13. The following information is provided for the year ended 31 December 2029:

	Revenue	Cost of Sales	Operating Expenses
Revenue	2200		
Cost of Sales		(1000)	
Operating Expenses			(440)
Profit	760		

14. The following information is provided for the year ended 31 December 2030:

	Revenue	Cost of Sales	Operating Expenses
Revenue	2300		
Cost of Sales		(1050)	
Operating Expenses			(460)
Profit	790		

15. The following information is provided for the year ended 31 December 2031:

	Revenue	Cost of Sales	Operating Expenses
Revenue	2400		
Cost of Sales		(1100)	
Operating Expenses			(480)
Profit	820		

16. The following information is provided for the year ended 31 December 2032:

	Revenue	Cost of Sales	Operating Expenses
Revenue	2500		
Cost of Sales		(1150)	
Operating Expenses			(500)
Profit	850		

17. The following information is provided for the year ended 31 December 2033:

	Revenue	Cost of Sales	Operating Expenses
Revenue	2600		
Cost of Sales		(1200)	
Operating Expenses			(520)
Profit	880		

18. The following information is provided for the year ended 31 December 2034:

	Revenue	Cost of Sales	Operating Expenses
Revenue	2700		
Cost of Sales		(1250)	
Operating Expenses			(540)
Profit	910		

19. The following information is provided for the year ended 31 December 2035:

	Revenue	Cost of Sales	Operating Expenses
Revenue	2800		
Cost of Sales		(1300)	
Operating Expenses			(560)
Profit	940		

20. The following information is provided for the year ended 31 December 2036:

	Revenue	Cost of Sales	Operating Expenses
Revenue	2900		
Cost of Sales		(1350)	
Operating Expenses			(580)
Profit	970		

21. The following information is provided for the year ended 31 December 2037:

	Revenue	Cost of Sales	Operating Expenses
Revenue	3000		
Cost of Sales		(1400)	
Operating Expenses			(600)
Profit	1000		

22. The following information is provided for the year ended 31 December 2038:

	Revenue	Cost of Sales	Operating Expenses
Revenue	3100		
Cost of Sales		(1450)	
Operating Expenses			(620)
Profit	1030		

23. The following information is provided for the year ended 31 December 2039:

	Revenue	Cost of Sales	Operating Expenses
Revenue	3200		
Cost of Sales		(1500)	
Operating Expenses			(640)
Profit	1060		

1. 1992年12月，在“中国—东盟首脑非正式会议”上，中国领导人正式提出建立中国—东盟自由贸易区。

4. *Phylogenetic relationships*—The phylogenetic relationships among the 10 species of *Phragmites* were determined using the parsimony method of Farris (1993) with the computer program PAUP (Farris 1993). The parsimony method was chosen because it is the most commonly used method for determining phylogenetic relationships (Mant 1993). The parsimony method was used to determine the most parsimonious tree (Mant 1993). The parsimony method was used to determine the most parsimonious tree (Mant 1993).

1. The first step in the process of identifying a problem is to define the problem. This involves identifying the symptoms of the problem and determining the scope of the problem. Once the problem has been defined, the next step is to identify the causes of the problem. This involves identifying the factors that are contributing to the problem and determining the root cause of the problem. Once the causes of the problem have been identified, the next step is to develop a plan to address the problem. This involves identifying the actions that need to be taken to address the problem and determining the resources that will be needed to implement the plan. Once a plan has been developed, the next step is to implement the plan. This involves taking the actions that have been identified in the plan and monitoring the progress of the plan. Finally, the last step in the process is to evaluate the results of the plan. This involves determining whether the plan has been successful in addressing the problem and identifying any lessons learned from the process.

Journal of Management Studies

1. 1990年12月29日，全国人大常委会通过了《中华人民共和国香港特别行政区基本法》。

1. The first step in the process is to identify the problem or issue that needs to be addressed. This involves gathering information and understanding the context of the problem.

X

La autenticidad de la firma fue demostrada bajo comparación.

(Firma) Ilegible
Dr. Mark Eichner
Notario de Basilea

POR COPIA CERTIFICADA

Basilea Suiza, este 30 días del mes de noviembre de 2010

Leg. Prot. 2568/2010

361

1. NAME

Mr. J. Edgar Hoover
Director
Federal Bureau of Investigation
Washington, D. C.

Dear Mr. Hoover:

I am writing to you regarding the

subject of the
recent report
concerning the

activities of the

Internal Security Committee

and the information received from the
various sources regarding the same.

I am sure that you will find this information of interest.

Sincerely,
J. Edgar Hoover

Enclosed for you are

8

APOSTILLA
(CONVENCION DE LA HAYA DEL 5 DE OCTUBRE DE 1961)

1. PAÍS: SUIZA
2. ESTE DOCUMENTO PÚBLICO HA SIDO FIRMADO POR: M. STAEHELIN
3. EN CALIDAD DE: NOTARIO PÚBLICO OFICIAL
4. CERTIFICADO CON EL SELLO DE: NOTARIO PÚBLICO ARRIBA MENCIONADO

CERTIFICÓ

5. EN BASILEA
6. EL 1 DE DICIEMBRE DE 2010
7. POR: LA CANCELLERÍA DEL ESTADO DE CANTON DE BASILEA
8. No. 7736/15937
9. SELLO: DE LA CANCELLERÍA DE ESTADO CIUDAD DE BASILEA
10. FIRMA: ilegible
Hanna Lauener

MINISTERIO DE
RELACIONES EXTERIORES

2011. ENE 28 P 5:54

JEFE DE LEGALIZACIONES
BOBOTA D.C.

NO SE ASUME
RESPONSABILIDAD
DEL TEXTO

046344

Maurice Vargas
CUYA FIRMA APARECE EN EL
DOCUMENTO DESEMPENA
LAS FUNCIONES INDICADAS.

MAURICE VARGAS
TRADUCTOR E INTERPRETE OFICIAL
INGLES - ESPAÑOL - ESPAÑOL - INGLÉS
FES. MARZO 1971 - 1981

1940

1940

1940

1940

1940

DEFENDERS EXHIBIT
MINISTERIO DE

1940

1940

1940

1940

1940

Industria y Comercio
SUPERINTENDENCIA

PLANILLA DE RADICACION - DIGITALIZACION DIARIA RELACION DE ANEXOS

Dependencia:		Fecha:		Recorrido:	
Tipo de Radicación:	Entrada:	Salida:	Traslado:	Convenio:	
Radicador:				Puntaje:	

Nº	No Radicación	Cant	Let
1	10-160879	3	17
2			
3			
4			
5			
6			
7			
8			
9			
10			
11			
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			

Item	Unidad de Conservación
1	CD
2	Disquetes
3	DVD
4	Fotos
5	Libro
6	Muestra Física
~~7~~	Otros
8	Planos
9	Periodico
10	Publicación Periodica
11	Sobre blanco tamaño carta
12	Sobre blanco tamaño oficio
13	Sobre de manila

Observaciones
Folio 9 5-115

(joint)

Patent Case 52533

ASSIGNMENT

9

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, we

Christopher ADAMS	citizen of United States Of America	Novartis Institutes for BioMedical Research, Inc. 400 Technology Square Cambridge, MA 02139 US
Qi-Ying HU	citizen of China	Novartis Institutes for BioMedical Research, Inc. 400 Technology Square Cambridge, MA 02139 US
Leslie Wighton MCQUIRE	citizen of United States Of America	Novartis Institutes for BioMedical Research, Inc. 400 Technology Square Cambridge, MA 02139 US
Julien PAPILLON	citizen of France	Novartis Institutes for BioMedical Research, Inc. 400 Technology Square Cambridge, MA 02139 US

do hereby sell, assign and transfer to Novartis AG, a company organized under the laws of the Swiss Confederation, of Lichtstrasse 35, 4056 Basel, Switzerland, (hereinafter referred to as the "**ASSIGNEE**") and its successors, assigns and legal representatives, all of my right, title and interest for all countries of the world in and to (1) all of my inventions and discoveries described in the patent application(s) titled

ORGANIC COMPOUNDS

and filed in the United States Patent and Trademark Office on _____, 20__ and accorded Application Number _____ * and/or filed in the RO/ _____ on _____, 20__ and accorded International Patent Application Number PCT/ _____ *, (2) the patent application(s) identified in (1), (3) all national stages of any international patent application identified in (1), (4) all other patent applications in all countries and regions claiming the priority of the provisional or non-provisional patent application filed in the United States Patent and Trademark Office on June 27, 2008 and accorded Application Number 61/076,452, (5) for all patent applications, all rights of priority based upon the United States patent application identified in (4) in all countries and regions under the Paris Convention for the Protection of Industrial Property, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application identified in (4) is a provisional patent application, under 35 USC 119(e) (including the right to file patent applications on said inventions and discoveries in the names of **ASSIGNEE** or their designees or in our names, at their election and in accordance with applicable law in all countries and regions), (6) all continuations and divisions of any United States patent application or international patent application designating the United States identified in (1), any national stages of any international application identified in (1) and any patent applications within the scope of (4) (including further continuations and divisions such as, but not limited to, continuations of continuations and continuations of divisions), ((2)-(4) and (6) hereinafter referred to collectively as "patent applications"), (7) all patents that are granted on any of said patent applications, (8) all registrations and confirmations of, and importation certificates based upon, one or more of said patents and applications for such registrations, confirmations and importation certificates and (9) all reissues, renewals and extensions of said patents, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said **ASSIGNEE** and their successors, assigns and legal representatives to the full ends of the terms for which said patents, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be

26h

10

granted, as fully and entirely as the same would have been held and enjoyed by us if this sale, assignment and transfer had not been made.

*We hereby authorize **ASSIGNEE** and their representatives to insert in this Assignment the filing date(s) and Application Number(s) of said patent application(s) when notified thereof.

And we hereby covenant and agree that we will, at any time, (i) upon the request, but at the expense, of **ASSIGNEE** or their successors, assigns or legal representatives execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, patent applications, patents, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates and applications within the scope of (8) and (9) in **ASSIGNEE** or their successors, assigns or legal representatives, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of **ASSIGNEE** or their successors, assigns or legal representatives execute all additional patent applications within the scope of (3), (4) and (6) and all applications within the scope of (8) or (9) and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of **ASSIGNEE** or their successors, assigns or legal representatives.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 03 day of April, 2009


Christopher M. Adams L.S.
Christopher ADAMS

ACKNOWLEDGEMENT

State of MASSACHUSETTS)
) s.s.:
County of MIDDLESEX)

On this 3 day of April, 2009, personally appeared before me
CHRISTOPHER ADAMS to me known and known by me to be the same person described
in and who executed the foregoing Assignment and acknowledged that (s)he executed the same of his (her)
own free will for the purpose set forth.

(Seal)



Allison Blake
Notary Public


Executed this first day of April, 2009

[Signature] L.S.
Qi-Ying HU

ACKNOWLEDGEMENT

State of MASSACHUSETTS)
County of MIDDLESEX) s.s.:

On this 1 day of APRIL, 2009, personally appeared before me
Qi-Ying HU to me known and known by me to be the same person described
in and who executed the foregoing Assignment and acknowledged that (s)he executed the same of his (her)
own free will for the purpose set forth.



[Signature]
Notary Public

Executed this first day of April, 2009

[Signature] L.S.
Leslie Wighton MCQUIRE

ACKNOWLEDGEMENT

State of MASSACHUSETTS)
County of MIDDLESEX) s.s.:

On this 1 day of APRIL, 2009, personally appeared before me
LESLIE WIGHTON MCQUIRE to me known and known by me to be the same person described
in and who executed the foregoing Assignment and acknowledged that (s)he executed the same of his (her)
own free will for the purpose set forth.

(Seal)



[Signature]
Notary Public

12

Executed this 01 day of April, 2009.

[Signature] L.S.

Julien PAPILLON

ACKNOWLEDGEMENT

State of MASSACHUSETTS)
County of MIDDLESEX) s.s.:

On this 1 day of April, 2009, personally appeared before me
JULIEN PAPILLON to me known and known by me to be the same person described
in and who executed the foregoing Assignment and acknowledged that (s)he executed the same of his (her)
own free will for the purpose set forth.

(Seal)

[Signature]
Notary Public



B

ACCEPTANCE OF ASSIGNMENT

With reference to the Assignment to **NOVARTIS AG** of an invention entitled "**ORGANIC COMPOUNDS**" signed by **Christopher ADAMS, Qi-Ying HU, Leslie Wighton MCQUIRE** and **Julien PAPILLON**; this will certify that **NOVARTIS AG** accepts such Assignment.

NOVARTIS AG

By :

E. Rutschmann



Name :

Ella Rutschmann

Sabine Zeller

Function :

Authorized Signatory

Authorized Signatory

Date:

14.04.2009

368

Attestation

I, the undersigned notary public in Basel, Switzerland, **Dr. Mark Eichner**, certify herewith that the above signatures are the genuine signatures of **Ms. Ella Rutschmann**, citizen of Lotzwil, Switzerland, residing in Basel, Switzerland, and of **Mr. Arthur Canonica**, citizen of Corticiasca, Switzerland, residing in Wisen, Switzerland both acting for **Novartis AG**, in Basel, Switzerland, both as proxy holders, both with joint signature.

The authenticity of the signatures was established by comparison.

BASEL, Switzerland, this 17th (seventeenth) day of April 2009 (two thousand and nine).

M. Eichner
Notar

Leg.Prot.Nr.: 80 /2009

15

FOR CERTIFIED COPY

I, the undersigned Civil Law Notary in Basel, Switzerland, Dr. Matthias Staehelin, hereby certify that the document attached heretofore is a true and authentic photocopy of the original document.

BASEL, Switzerland, this 30th (thirtieth) day of November 2010 (two thousand and ten)

M. Staehelin *Notar*
Dr. M. Staehelin
Notar

Leg.Prot.Nr. 2568 /2010

APOSTILLE
(Hague Convention of October 5th, 1961)

1. Country: Switzerland (Schweiz / Suisse)
This official document

2. is signed by *Dr. iur. M. Staehelin*

3. in his/her function as *notary public*

4. and certified by the seal of the *above mentioned*

Certified

5. in Basel (Bâle) 6. on *- 1. Dez. 2010*

7. by the State Chancery of the Canton of Basel-Stadt

8. no. *7736 / 15937*

9. Seal / stamp: 10. Signature: *H. Lauener*
Hanna Lauener

